Objective: To determine whether renal angiomyolipomas
from women with pulmonary lymphangioleiomyomatosis (LAM) express
estrogen receptor (ER) and progesterone receptor (PR).
Design: Retrospective study of archival tissue.
Patients: Twelve women with LAM and angiomyolipomas.
Setting: Fox Chase Cancer Center.
Interventions: ER and PR expression was studied using
immunohistochemistry. The hormonal status of the patients at the time
of resection of the angiomyolipoma was determined.
Results: Ten of the angiomyolipomas had ER immunoreactivity
(83%), and all 12 had PR immunoreactivity (100%). The ER and PR
positivity was in the smooth muscle component of the angiomyolipomas
only. For five women, pulmonary LAM specimens were also available; two
were ER positive (40%), and all five were PR positive (100%). All
four angiomyolipomas from women receiving progesterone therapy were ER
and PR positive. One tumor from a woman receiving tamoxifen was ER
negative and strongly PR positive. One woman was pregnant; her tumor
was ER and PR positive.
Conclusions: ER and PR
expression is frequent in renal angiomyolipoma cells from women with
LAM. PR was more consistently present than ER in angiomyolipomas and in
LAM. Our data suggest that angiomyolipoma growth could be affected by
hormonal factors. If the growth of LAM-associated angiomyolipomas slows
during hormonal therapy, there are two potential implications for LAM
patients: first, angiomyolipoma size could serve as a measurable
indication of response to hormonal therapy; and second, surgical
removal of angiomyolipomas might be avoided in some